Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So improving momentum throughout fiscal '24 so far, expectations of continued momentum into Q4 |
| And we've had a strong and growing dividend for many, many years, over 40 years |
| Medtronic has been on a strong turnaround trajectory |
| Karen Parkhill Yeah, again EV-ICD is another great product in our pipeline that we expect to be a really long-term driver for us to come, just like Micra was with our Cardiac Rhythm Management business, where we had breakthrough innovation in that business and it's been a really strong driver for us and a way for us to continue to capture market share, same with EV-ICD |
| It's coming out soon to a theater near you, and we expect good results |
| Our strong confidence in driving that durable mid-single-digit top-line and ultimately that leveraged P&L and double-digit shareholder return |
| I'm hoping that you are taking away our really strong confidence in our future |
| We have been driving a significant turnaround in that business and we are super pleased with the performance and the trajectory from here |
| And we're really excited about that durability continuing |
| We've delivered really strong growth with the 780G [Technical Difficulty] over in Europe |
| And so, really strong headcount management to help drive that leverage |
| Our Evolut FX, especially in the small annular space is highly-differentiated and we're not stopping with that, we've got Evolut FX Plus coming out soon too, and so we expect to compete very well |
| And we've had really strong disciplined headcount management across the company |
| The feedback that we get continues to be super strong |
| We've also been driving a really strong performance-driven culture focused on execution, focused on doing and delivering what we say we're going to do |
| And you're seeing that happen on the top-line and we're driving the earnings power and transformation down the bottom-line and it starts with stabilizing and improving our gross margin, which we are incredibly focused on, ultimately delivering pricing and cost down ahead of inflation, and then leverage down the P&L on SG&A to ultimately drive [Technical Difficulty] a strong and growing bottom-line, which when paired with our really strong and growing dividend, delivers a double-digit total shareholder return |
| So cardiac ablation is another area that's going to be a really good long-term growth driver for the company for many years to come |
| So super excited about our bright future |
| When you look at our really strong pipeline, this is the best pipeline we've ever had across the company |
| Last quarter was a really strong quarter for diabetes, where we returned to growth in the United States and ultimately globally for the business delivered more than 10% growth in the quarter, and we're just starting from here |
| We began to see that a bit in the third quarter, and ultimately, we're going to be focused on driving that strong bottom-line paired with our strong and growing dividend that leads to a double-digit total shareholder return |
| We're really bullish about our durable mid-single-digit top-line |
| We've got the seven-day insertions that you mentioned now that is highly-differentiated and we've got great feedback on that |
| We're going to be submitting to the FDA in the first half of the calendar year for our 780G and Simplera Sync, and so the diabetes franchise is back and just improving from here |
| So feedback continues really strong |
| Listen, thrilled to be here, and thrilled to be talking about Medtronic, because we are on a really great trajectory |
| We are super excited about what we've got in our pipeline there |
| And then on a long going trajectory, we've got renal denervation coming, and just super, super excited about our pipeline |
| Karen Parkhill We had strong growth outside the US and we're expecting that in the US and globally |
| We're getting amazing feedback both on PulseSelect, the single-shot, and on our Affera |
| Statement |
|---|
| There is -- there has been some disappointment in the community and this is going back, say, five years as to when we're going to see innovation and new products coming out of Medtronic |
| Matt Miksic On the sensor, and forgive me, but I think it's fair to say that investors have been skeptical about the turnaround |
| Currency has been a headwind for us |
| So, currency still a headwind |
| And -- I mean, the current status is that that business was -- in the US was down in fiscal Q3 |
| So I'd be remiss not to talk about what that impact looks like on the top-line while we're talking about the top-line, there's been a delay in some of those VBP programs |
| If we look at rates recently at the time of our earnings call, it's likely to still be a headwind for us |
| That said, there are some minor delays that we've had in parts of neurovascular and parts of aortic, where some tenders have moved from provincial tenders to national tenders and that's just a little bit of a delay |
| But a headwind that's come down because the biggest headwind we faced was in FY '23 on the top-line, and that takes time to go through the bottom-line as we have our hedges in place |
| So larger cell design potentially going to chip away at that sort of competitive disadvantage, if you could call it that |
| So, Structural Heart is a highly competitive market and we are fiercely competitive in that market, and we wouldn't be doing a head-to-head trial if we weren't really confident about the results of it, we'll see |
| But at the end of the day, that doesn't change the bullishness that we feel right now |
| Took headcount -- indirect headcounts down at the beginning of last year |
| The competitive environment in the US has changed quite a bit, even though there's one incumbent competitor |
Please consider a small donation if you think this website provides you with relevant information